New Therapy for Severe Cystic Acne

Publisher Website
Google Scholar
Abstract
Isotretinoin, 13-cis-retinoic acid (Accutane, Hoffmann-LaRoche), is brightening the bleak outlook for adolescents and young adults with nodular, cystic, and conglobate acne—a severe, scarring disease—that has resisted treatment with topical or systemic antibiotics, benzoyl peroxide, retinoic acid, and intralesional corticosteroids. Adolescents with less severe forms of acne who learn about the therapeutic triumphs of isotretinoin in severe recalcitrant nodular and cystic acne may assume that the drug also would be beneficial for them. Pediatricians should inform these adolescents that the drug has not been studied in, found effective for, or labeled for the treatment of typical acne. Patients with multiple, active, deep dermal or subcutaneous cystic and nodular acne lesions are usually given 1 to 2 mg of isotretinoin per kilogram of body weight per day (although dosage as low as 0.05 mg/kg/d has been reported as beneficial), orally, in two divided doses for 15 to 20 weeks or until the cyst count decreases by 70%, if this happens sooner than 15 to 20 weeks. Use of this drug is associated with a reduction in sebaceous gland size and activity (a decrease in sebum excretion by as much as 75% to 90%), with inhibition of sebaceous cell differentiation, and with a reversion to prepubertal skin surface lipid composition. Although isotretinoin is expensive, a course of treatment usually clears the troublesome lesions and a prolonged remission often follows. Side effects and alterations in patients' laboratory test results do occur; these appear to be lessened by reduction in dosage and to be fully reversible when the drug is discontinued.

This publication has 0 references indexed in Scilit: